Psoriasis is a chronic inflammatory skin disorder with a pathogenesis involving the interleukin-23/interleukin-17 axis. Salvianolic acid B exerts several pharmacological effects, such as antioxidation, anti-inflammation, and antitumor effects. The anti-psoriatic effects of salvianolic acid B have not been reported. In this study, we aimed to determine the optimum vehicle for salvianolic acid B, investigate its therapeutic effect on psoriatic-like skin conditions, and explore its underlying mechanisms of action. BALB/c mice were administered topical imiquimod to induce psoriasis-like skin and were then randomly assigned to control, vehicle control, salvianolic acid B in vehicles, and 0.25% desoximetasone ointment treatment groups. Barrier function, cytokine expression, histology assessment, and disease severity were evaluated. The results showed that salvianolic acid B-containing microemulsion alleviated disease severity, reduced acanthosis, and inhibited interleukin-23/interleukin-17 (IL-23/IL-17) cytokines, epidermal proliferation, and increased skin hydration. Our study suggests that salvianolic acid B represents a possible new therapeutic drug for the treatment of psoriasis. In addition, such formulation could obtain high therapeutic efficacy in addition to providing sufficient hydration for dry skin.

中文翻译：

---

微乳剂中的丹酚酸B为干性皮肤提供了充分的水合作用，并改善了咪喹莫特诱发的牛皮癣样皮炎的小鼠严重程度。

牛皮癣是一种慢性炎性皮肤疾病，其发病机制涉及白介素23 /白介素17轴。丹酚酸B具有多种药理作用，例如抗氧化，抗发炎和抗肿瘤作用。丹酚酸B的抗银屑病作用尚未见报道。在这项研究中，我们旨在确定丹酚酸B的最佳载体，研究其对银屑病样皮肤病的治疗效果，并探讨其潜在的作用机制。将BALB / c小鼠局部给予咪喹莫特以诱导牛皮癣样皮肤，然后将其随机分为对照组，赋形剂对照，赋形剂中的丹酚酸B和0.25％的地塞米松酮软膏治疗组。评估屏障功能，细胞因子表达，组织学评估和疾病严重程度。结果表明，含丹酚酸B的微乳液可减轻疾病的严重程度，减少棘皮症，并抑制白介素23 /白介素17（IL-23 / IL-17）细胞因子，表皮增生和增加皮肤水合作用。我们的研究表明丹酚酸B代表一种可能的治疗牛皮癣的新治疗药物。另外，除了为干性皮肤提供足够的水合作用外，这种制剂还可以获得高治疗功效。